CoChat

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Open access
Lv, Yi-Qing, Yuan, Lin, Sun, Yan, Dou, Hao-Wen, Su, Ji-Hui, Hou, Zhi-Pan, Li, Jia-Yi, Li, Wen · 2022 · Translational Neurodegeneration

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Abstract

Background: Growing evidence suggests an association between Parkinson’s disease (PD) and diabetes mellitus (DM). At the cellular level, long-term elevated levels of glucose have been shown to lead to nigrostriatal degeneration in PD models. However, the underlying mechanism is still unclear. Previously, we have elucidated the potential of type 2 diabetes mellitus (T2DM) in facilitating PD progression, involving aggregation of both alpha-synuclein (α-syn) and islet amyloid polypeptide in the pancreatic and brain tissues. However, due to the complicated effect of insulin resistance on PD onset, the actual mechanism of hyperglycemia-induced dopaminergic degeneration remains unknown. Methods: We employed the type 1 diabetes mellitus (T1DM) model induced by streptozotocin (STZ) injection in a transgenic mouse line (BAC-α-syn-GFP) overexpressing human α-syn, to investigate the direct effect of elevated blood glucose on nigrostriatal degeneration. Results: STZ treatment induced more severe pathological alterations in the pancreatic islets and T1DM symptoms in α-syn-overexpressing mice than in wild-type mice, at one month and three months after STZ injections. Behavioral tests evaluating motor performance confirmed the nigrostriatal degeneration. Furthermore, there was a marked decrease in dopaminergic profiles and an increase of α-syn accumulation and Serine 129 (S129) phosphorylation in STZ-treated α-syn mice compared with the vehicle-treated mice. In addition, more severe neuroinflammation was observed in the brains of the STZ-treated α-syn mice. Conclusion: Our results solidify the potential link between DM and PD, providing insights into how hyperglycemia induces nigrostriatal degeneration and contributes to pathogenic mechanisms in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-022-00288-z

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 STZ treatment reduces the body weight and induces more severe hyperglycemia in α-syn-overexpressing mice. (a) Schematic of the experimental design. Both WT and BAC-α-syn-GFP mice were injected (i.p.) with STZ or vehicle. Body weight and blood glucose level were routinely monitored throughout the experiment. The mice were subjected to behavioral tests at one month and three months after injections. (b) Percentage of survival at 12 weeks after STZ i.p. injections. (c, d) Body weight and blood glucose alterations after STZ i.p. injections. The number of mice per group was provided in Additional file 1: Table S1. ****P < 0.0001 α-syn + STZ versus α-syn + vehicle, ####P < 0.0001 WT + STZ versus WT + vehicle, $P < 0.05 WT + STZ versus α-syn + STZ
Fig. 1 STZ treatment reduces the body weight and induces more severe hyperglycemia in α-syn-overexpressing mice. (a) Schematic of the experimental design. Both WT and BAC-α-syn-GFP mice were injected (i.p.) with STZ or vehicle. Body weight and blood glucose level were routinely monitored throughout the experiment. The mice were subjected to behavioral tests at one month and three months after injections. (b) Percentage of survival at 12 weeks after STZ i.p. injections. (c, d) Body weight and blood glucose alterations after STZ i.p. injections. The number of mice per group was provided in Additional file 1: Table S1. ****P < 0.0001 α-syn + STZ versus α-syn + vehicle, ####P < 0.0001 WT + STZ versus WT + vehicle, $P < 0.05 WT + STZ versus α-syn + STZCC BY · PubMed Central
Fig. 2 STZ treatment exacerbates structural damage of islets in α-syn-overexpressing mice compared to WT. (a) Representative microscopic images of immunohistochemical staining with antibody against insulin at one and three months after injections, in the pancreatic islets of WT + vehicle, WT + STZ, α-syn + vehicle and α-syn + STZ groups. (b) Quantification of average percentage of islet β-cell area to the total islet area in pancreas of WT and BAC-α-syn-GFP mice with i.p. injections of STZ or vehicle (n = 3 to 4 mice/group). Scale bar, 50 µm. *P < 0.05, ***P < 0.001, ****P < 0.0001
Fig. 2 STZ treatment exacerbates structural damage of islets in α-syn-overexpressing mice compared to WT. (a) Representative microscopic images of immunohistochemical staining with antibody against insulin at one and three months after injections, in the pancreatic islets of WT + vehicle, WT + STZ, α-syn + vehicle and α-syn + STZ groups. (b) Quantification of average percentage of islet β-cell area to the total islet area in pancreas of WT and BAC-α-syn-GFP mice with i.p. injections of STZ or vehicle (n = 3 to 4 mice/group). Scale bar, 50 µm. *P < 0.05, ***P < 0.001, ****P < 0.0001CC BY · PubMed Central
Fig. 3 Long-term hyperglycemia aggravates motor deficits in α-syn-overexpressing mice. Motor performance at one and three months after injections in the pole test (a, b) and open field test (c–f). T-turn (a) and T-total (b) increased in the STZ-treated α-syn compared to vehicle. (c–f) In the open field test that assesses the spontaneous activity of mice, the mean speed in total zone (c), the total distance (d), the distance in the central zone (e) and the distance in the peripheral zone (f) differed between the α-syn + STZ and WT + vehicle groups. At least three mice were included in each group. The number of mice per group was provided in Additional file 1: Table S1. *P < 0.05, ***P < 0.001, ****P < 0.0001
Fig. 3 Long-term hyperglycemia aggravates motor deficits in α-syn-overexpressing mice. Motor performance at one and three months after injections in the pole test (a, b) and open field test (c–f). T-turn (a) and T-total (b) increased in the STZ-treated α-syn compared to vehicle. (c–f) In the open field test that assesses the spontaneous activity of mice, the mean speed in total zone (c), the total distance (d), the distance in the central zone (e) and the distance in the peripheral zone (f) differed between the α-syn + STZ and WT + vehicle groups. At least three mice were included in each group. The number of mice per group was provided in Additional file 1: Table S1. *P < 0.05, ***P < 0.001, ****P < 0.0001CC BY · PubMed Central
Fig. 4 Long-term hyperglycemia causes degeneration of dopaminergic neuronal profile in α-syn-overexpressing mice. (a) Western blot analyses of TH, DAT and NeuN protein levels in mouse SNpc. (b–d) Quantification of TH, DAT and NeuN protein levels (n = 3 to 4 mice/group). (e) Representative coronal mesencephalic sections with immunohistochemical staining of TH in the SN. (f) High-magnification images corresponding to the SNpc area indicated in (e4), (e7), and (e8). (g) Quantitative analyses of TH-positive neurons determined by stereology in the midbrain region. WT + vehicle (n = 4/4 mice at one/three months after injections, respectively); WT + STZ (n = 5/3 mice at one/three months after injections, respectively); α-syn + vehicle (n = 4/4 mice at one/three months after injections, respectively); α-syn + STZ (n = 4/3 mice at one/three months after injections, respectively). Scale bars, 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4 Long-term hyperglycemia causes degeneration of dopaminergic neuronal profile in α-syn-overexpressing mice. (a) Western blot analyses of TH, DAT and NeuN protein levels in mouse SNpc. (b–d) Quantification of TH, DAT and NeuN protein levels (n = 3 to 4 mice/group). (e) Representative coronal mesencephalic sections with immunohistochemical staining of TH in the SN. (f) High-magnification images corresponding to the SNpc area indicated in (e4), (e7), and (e8). (g) Quantitative analyses of TH-positive neurons determined by stereology in the midbrain region. WT + vehicle (n = 4/4 mice at one/three months after injections, respectively); WT + STZ (n = 5/3 mice at one/three months after injections, respectively); α-syn + vehicle (n = 4/4 mice at one/three months after injections, respectively); α-syn + STZ (n = 4/3 mice at one/three months after injections, respectively). Scale bars, 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001CC BY · PubMed Central
Fig. 5 Hyperglycemia increases α-syn aggregation and phosphorylation in the nigrostriatal system in α-syn-overexpressing mice. (a) Western blot analyses of α-syn and phosphorylated α-syn (pS129) levels in mouse SN. (b, c) Quantification of α-syn and pS129-α-syn protein levels (n = 3 to 4 mice/group). (d) Western blot analyses of Triton-soluble α-syn (Trx soluble) and Triton-insoluble α-syn (Trx insoluble) in mouse SN. (e–f) Quantification of relative expression of Trx-soluble and Trx-insoluble α-syn by intensity measurement (n = 3 per group). (g) Representative immunohistochemical images of pS129-α-syn in the SN of WT and BAC-α-syn-GFP mice at one and three months after injections. Images in the right column are higher magnifications of boxed areas in the left column. (h) Representative images of two different types of pS129-α-syn-positive nigral neurons. h1 and h2 show neurons containing pS129-positive inclusions, while h3 shows a neuron with diffused staining. h4 shows the pS129 staining in SN reticulata, where significant positive profile is present in BAC mice (right panel). (i, j) Stereological quantification of pS129-α-syn-positive nigral neurons in the SNpc (i) and the proportion of remaining nigral neurons containing α-syn inclusions (j). WT + vehicle (n = 4/4 mice at one/three months after injections, respectively); WT + STZ (n = 4/3 mice at one/three months after injections, respectively); α-syn + vehicle (n = 4/4 mice at one/three months after injections, respectively); α-syn + STZ (n = 4/4 mice at one/three months after injections, respectively). Scale bars: (g) left column, 200 µm; right column, 50 µm; (h) h1–h3, 10 µm; h4, 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
Fig. 5 Hyperglycemia increases α-syn aggregation and phosphorylation in the nigrostriatal system in α-syn-overexpressing mice. (a) Western blot analyses of α-syn and phosphorylated α-syn (pS129) levels in mouse SN. (b, c) Quantification of α-syn and pS129-α-syn protein levels (n = 3 to 4 mice/group). (d) Western blot analyses of Triton-soluble α-syn (Trx soluble) and Triton-insoluble α-syn (Trx insoluble) in mouse SN. (e–f) Quantification of relative expression of Trx-soluble and Trx-insoluble α-syn by intensity measurement (n = 3 per group). (g) Representative immunohistochemical images of pS129-α-syn in the SN of WT and BAC-α-syn-GFP mice at one and three months after injections. Images in the right column are higher magnifications of boxed areas in the left column. (h) Representative images of two different types of pS129-α-syn-positive nigral neurons. h1 and h2 show neurons containing pS129-positive inclusions, while h3 shows a neuron with diffused staining. h4 shows the pS129 staining in SN reticulata, where significant positive profile is present in BAC mice (right panel). (i, j) Stereological quantification of pS129-α-syn-positive nigral neurons in the SNpc (i) and the proportion of remaining nigral neurons containing α-syn inclusions (j). WT + vehicle (n = 4/4 mice at one/three months after injections, respectively); WT + STZ (n = 4/3 mice at one/three months after injections, respectively); α-syn + vehicle (n = 4/4 mice at one/three months after injections, respectively); α-syn + STZ (n = 4/4 mice at one/three months after injections, respectively). Scale bars: (g) left column, 200 µm; right column, 50 µm; (h) h1–h3, 10 µm; h4, 50 µm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001CC BY · PubMed Central
Fig. 6 Hyperglycemia promotes neuroinflammation in BAC-α-syn-GFP mice. (a) Representative Western blots of Iba-1 and GFAP. (b, c) Quantification of Iba-1 and GFAP protein levels by intensity measurement (n = 3 to 4 mice/group). (d) Representative immunohistochemical Iba-1 staining of the SN of mice. (e) Number of SN microglia at each time point. (f) The morphology of SN microglia at four different activation stages. (g) The proportion of four types of microglia based on different morphology. WT + vehicle (n = 4/4 mice at one/three months after injection, respectively); WT + STZ (n = 4/4 mice at one/three months after injection, respectively); α-syn + vehicle (n = 3/4 mice at one/three months after injection, respectively); α-syn + STZ (n = 3/4 mice at one/three months after injection, respectively). Scale bars: (d), left column, 100 µm; right column, 50 µm; (f), 20 µm. *P < 0.05, **P < 0.01 in (b, c, e). *P < 0.05, **P < 0.01 α-syn + STZ versus α-syn + vehicle in stage IV at one and three months after injection (g)
Fig. 6 Hyperglycemia promotes neuroinflammation in BAC-α-syn-GFP mice. (a) Representative Western blots of Iba-1 and GFAP. (b, c) Quantification of Iba-1 and GFAP protein levels by intensity measurement (n = 3 to 4 mice/group). (d) Representative immunohistochemical Iba-1 staining of the SN of mice. (e) Number of SN microglia at each time point. (f) The morphology of SN microglia at four different activation stages. (g) The proportion of four types of microglia based on different morphology. WT + vehicle (n = 4/4 mice at one/three months after injection, respectively); WT + STZ (n = 4/4 mice at one/three months after injection, respectively); α-syn + vehicle (n = 3/4 mice at one/three months after injection, respectively); α-syn + STZ (n = 3/4 mice at one/three months after injection, respectively). Scale bars: (d), left column, 100 µm; right column, 50 µm; (f), 20 µm. *P < 0.05, **P < 0.01 in (b, c, e). *P < 0.05, **P < 0.01 α-syn + STZ versus α-syn + vehicle in stage IV at one and three months after injection (g)CC BY · PubMed Central
Fig. 7 Co-localization of Iba-1 and MHC class II in the striatum of mice. (a) Representative images of double-immunofluorescence staining of MHC class II and Iba-1 in the striatum of WT and BAC-α-syn-GFP mice with vehicle or STZ injections. (b) Pearson’s coefficient of co-localization between Iba-1 and MHC class II in the striatum (n = 4 mice per group). Scale bars, 50 µm. *P < 0.05, ***P < 0.001, ****P < 0.0001
Fig. 7 Co-localization of Iba-1 and MHC class II in the striatum of mice. (a) Representative images of double-immunofluorescence staining of MHC class II and Iba-1 in the striatum of WT and BAC-α-syn-GFP mice with vehicle or STZ injections. (b) Pearson’s coefficient of co-localization between Iba-1 and MHC class II in the striatum (n = 4 mice per group). Scale bars, 50 µm. *P < 0.05, ***P < 0.001, ****P < 0.0001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Cited by

See all 83

Metadata

Authors
Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J.-Y., & Li, W.
Affiliations
  • China Medical University (CN)
  • Lund University (SE)
Corresponding author
Li, Wen
Venue
Translational Neurodegeneration
Published
2022-03-07
Volume
11
Issue
1
Pages
14-14
ISSN
2047-9158 (ISSN-L)
OpenAlex
W4220880286
Cited by
82
References
70
Citations by year
2026: 14 · 2025: 24 · 2024: 31 · 2023: 8 · 2022: 5
FWCI
9.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Natural Science Foundation of China (81430025, 31800898, U1801681)
  • Key Field Research Development Program of Guangdong Province (2018B030337001)
  • The Swedish Research Council (2019-01551)
  • EU-JPND research (αSynProtec, REfrAME)
  • EU-Horizon2020 (MSCA-ITN-2016)
  • ParkinsonFonden, the Strategic Research Area Multipark (Multidisciplinary research in Parkinson’s disease at Lund University)
  • Svenska Sällskapet för Medicinsk Forskning (SSMF, P18-0194)
  • Hjärnfodens (PS2018-0062)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Parkinson's disease, hyperglycemia, type 1 diabetes, streptozotocin-induced diabetes, alpha-synuclein aggregation, dopaminergic neuron loss, nigrostriatal degeneration, neuroinflammation
MeSH terms
Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Disease Models, Animal, Dopamine, Hyperglycemia, Mice, Transgenic, Parkinson Disease, Mice, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. https://app.cochat.ai/papers/10.1186/s40035-022-00288-z
The paper
Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J.-Y., & Li, W. (2022). Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. Translational Neurodegeneration. https://doi.org/10.1186/s40035-022-00288-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.